Search Results
Jan 08, 2026, 09:00 ET Enliven Reports Positive Initial Phase 1b Data for ELVN-001 in CML and Outlines 2026 Clinical Milestones
UpdatesELVN-001 is a potent, highly selective, potentially best-in-class small molecule kinase inhibitor designed to specifically target the BCR::ABL gene fusion, the oncogenic driver for patients with CML. Encouraging ELVN-001 Phase 1b Data by 24 WeeksAs of the
More news about: Enliven Therapeutics, Inc.
Jan 08, 2026, 08:55 ET New Research Highlights Distinct Support for Immune-Balancing Activity in Lion's Mane Mushroom Mycelium as Compared to Fruiting Body Extracts
pathways while exhibiting comparatively lower inflammatory signaling than the fruiting body extract at baseline in vitro.*Upon revealing the global gene expression patterns elicited by Host Defense Lion's Mane in cultured human immune cells, the researchers sought further substantiation, revealing clear
More news about: Fungi Perfecti, LLC
Jan 08, 2026, 08:50 ET Aspen Neuroscience Completes Phase 1/2a ASPIRO Trial Cohort Three Dosing and State-of-the-Art Manufacturing Expansion, Paving the Way for Developing Transformative Therapies for Patients
provided by the California Institute for Regenerative Medicine (CIRM), a state of California agency that supports regenerative medicine, stem cell, and gene therapy research, which enabled Cohorts 1 and 2.
More news about: Aspen Neuroscience, Inc.
Jan 08, 2026, 08:30 ET Detecting and Characterizing RNA Drug Candidates to Accelerate Therapeutic Development, Upcoming Webinar Hosted by Xtalks
RNA-target interactions across the transcriptome, these assays reveal where siRNAs bind, how they influence RNA processing and their downstream impact on gene expression, offering a powerful, data-driven view of specificity and efficacy.Together, these complementary technologies provide a comprehensive
More news about: Xtalks
Jan 08, 2026, 08:00 ET Klotho Neurosciences to Present at the Biotech Showcase 2026
(NASDAQ: KLTO) is a biogenetics company focused on the development of innovative, disease-modifying cell and gene therapies using a protein derived from a patented form of the "anti-aging" human Klotho gene (s-KL), and its novel delivery systems to transform and improve the treatment of neurodegenerative and
More news about: Klotho Neurosciences, Inc.
Jan 08, 2026, 08:00 ET Factorial Biotechnologies and Honeycomb Biotechnologies Partner to Deliver High-Throughput, Instrument-Free Single-Cell DNA Sequencing
profiling."Extending the HIVE platform to instrument-free single-cell DNA sequencing will accelerate discoveries in somatic mosaicism, tumor evolution, and gene editing by enabling large-scale, single-cell genomic studies," added Chris Love, Co-Founder of Honeycomb Biotechnologies and Professor of Chemical Engineering
More news about: Factorial Biotechnologies
Jan 08, 2026, 04:00 ET Complement Therapeutics Announces FDA Fast Track Designation for CTx001 for the Treatment of Geographic Atrophy Secondary to AMD
designation has been granted to CTx001 for Geographic Atrophy secondary to Age-related Macular DegenerationCTx001 is an investigational AAV-based gene therapy designed to modulate multiple pathways of the complement systemCTx001 has previously received FDA IND clearance and will be evaluated
More news about: Complement Therapeutics
Jan 08, 2026, 03:30 ET Seasoned biotherapeutics leader Thomas J. Farrell joins NanoSyrinx as CEO to advance Nanosyringe-enabled intracellular medicines
$500 million in funding– Expertise in advanced therapeutics development, driving multiple cell and gene therapy product candidates from discovery through to clinical trials COVENTRY, England, Jan.
More news about: NanoSyrinx
Jan 08, 2026, 03:00 ET Independent Dutch Study Further Validates Merlin CP-GEP Test for Melanoma Prognosis
prediction model for cutaneous melanoma patients and is the only commercially available GEP test that combines clinicopathologic (CP) variables with gene expression profiling (GEP) into a single integrated algorithm. In addition, it is the only GEP test that provides binary stratification of all patients
More news about: SkylineDx
Jan 08, 2026, 00:01 ET Biopharma's Innovation Engine Powers Ahead, but Its Business Model Faces Mounting Strain
this growth are changing. From 2010 to 2020, many biopharma companies targeted development of biologics and novel modalities such as CAR-T, siRNA, and gene therapy, that targeted diseases affecting smaller populations. Since 2020, there has been a re-emergence of therapeutics targeting diseases affecting
More news about: Boston Consulting Group (BCG)
Jan 07, 2026, 14:10 ET American Society of Gene & Cell Therapy and Orphan Therapeutics Accelerator Partner to Advance and Commercialize Promising Rare Disease Treatments
catalyze development of deprioritized cell and gene therapies, supported by AI-enabled platformMILWAUKEE and CAMBRIDGE, Mass., Jan. 7, 2026 /PRNewswire/ -- The American Society of Gene & Cell Therapy (ASGCT), the leading
More news about: American Society of Gene & Cell Therapy and Orphan Therapeutics Accelerator
Jan 07, 2026, 10:30 ET Pharmaceutical Microfiltration Market worth $9.94 billion by 2030 | MarketsandMarkets™
driving force behind this shift is the increasing production of biologics, biosimilars, and advanced therapies, such as mRNA vaccines and cell & gene therapies. This surge in production is creating a higher demand for high-performance consumables, including depth filters, membrane filters, virus-retentive
More news about: MarketsandMarkets
Jan 07, 2026, 08:00 ET STRM.BIO Raises $8 Million in Series Seed 2 Financing to Advance Non-Viral Gene Delivery Platform for In Vivo Cell Engineering and Gene Therapy
diseases."The company's MV platform for in vivo gene therapy represents a novel, non-viral, cell-derived delivery modality with the potential to overcome many of the key barriers limiting current viral and synthetic in vivo gene delivery systems. The platform enables precise, efficient,
More news about: STRM.BIO
Jan 07, 2026, 07:33 ET Rakuten Medical Raises $100 Million in Oversubscribed Series F to Accelerate Development Toward U.S. Regulatory Approval
and Axil Capital, a Japanese venture capital firm supported by the Mizuho Group. TaiAx's investment focus broadly covers first-in-class therapeutics, gene and cell therapies and AI-driven medical products, among other novel technologies addressing unmet medical needs. The TaiAx team is actively evaluating
More news about: Rakuten Medical, Inc.
Jan 07, 2026, 07:00 ET Genprex Provides Clinical Update on Diabetes Gene Therapy Program
GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced a clinical program update on its diabetes gene therapy program for GPX-002, the Company's diabetes gene therapy drug candidate, detailing recent
More news about: Genprex, Inc.
Jan 07, 2026, 07:00 ET AL-S Pharma to present at the upcoming J. P. Morgan 2026 Annual Healthcare Conference on Thursday, January 15
tolerability, pharmacodynamic (PD) markers, and pharmacokinetics (PK) of AP-101 in patients with sporadic ALS and in patients with mutations in the SOD1 gene.About AL-S Pharma AG AL-S Pharma is a Swiss-based single-asset company founded and co-owned by Neurimmune and TVM Capital Life
More news about: AL-S Pharma AG
Jan 07, 2026, 04:00 ET Nucleome Therapeutics nominates first preclinical development candidate
strategic deployment of machine learning and other computational methods has advanced genetics to an unprecedented level by deciphering patterns of gene regulation from the 3D architecture of the genome. This has redefined what genetic variation can reveal about disease, for both drug target discovery
More news about: Nucleome Therapeutics
Jan 06, 2026, 16:04 ET Advances in maternal-fetal and neonatal diagnostics highlighted in special January issue of ADLM's Clinical Chemistry journal
sequencing the DNA of pediatric cancer patients and links specific sequences to tumor risk. A perspective article describes how CRISPR, a groundbreaking gene-editing technique, was used to treat an infant with urea cycle disorder, an inherited metabolic disease. Adopting informaticsNow
More news about: Association for Diagnostics & Laboratory Medicine (ADLM)
Jan 06, 2026, 13:32 ET Ziihera® (zanidatamab-hrii) Combinations Achieve Unprecedented Results in First-Line HER2+ Locally Advanced or Metastatic GEA Including More Than Two Years Median Overall Survival Benefit
developed the molecule. The FDA granted Breakthrough Therapy designation for zanidatamab's development in patients with previously treated HER2 gene-amplified BTC, and two Fast Track designations for zanidatamab: one as a single agent for refractory BTC and one in combination with standard-of-care
More news about: Jazz Pharmaceuticals plc
Jan 06, 2026, 10:30 ET Cell Culture Reagents Market worth $8.95 billion by 2030 | MarketsandMarkets™
antibiotics/antimycotics, cryoprotective reagents, contamination detection kits, and other cell culture reagents. This is driven by the rapid scale-up of cell and gene therapy programs, in which growth factors and cytokines are repeatedly used for cell activation, expansion, and differentiation. Adoption is also rising
More news about: MarketsandMarkets
Jan 06, 2026, 09:30 ET Lung Cancer Research Foundation Announces Additional 2025 Scientific Research Grant Awards
basic lung cancer biology at a broad biochemical level. It will deliver new knowledge regarding the mechanisms oncogenic KRAS employs to deregulate gene expression and metabolism, and it will supply new diagnostic assays and therapeutic tools that can translate to the clinic to help patients with lung
More news about: Lung Cancer Research Foundation
Jan 06, 2026, 09:15 ET Illumina launches powerful software for connected, intuitive, and scalable multiomic analysis
Both single cell and spatial analysis on Connected Multiomics provide differential expression, marker gene identification, and cell typing. For spatial transcriptomics, Connected Multiomics overlays gene expression data on tissue imagery to provide rich spatial context for biological insights.Illumina
More news about: Illumina, Inc.
Jan 06, 2026, 09:00 ET The Reeve Foundation and Spinal Research Award New Grants to Advance Traumatic Spinal Cord Injury Treatments
studies focused on developing new treatments for traumatic spinal cord injury (SCI). These projects include work on new or repurposed drugs, biologics and gene therapies aimed at protecting nerve cells, promoting regeneration, and improving recovery.A major challenge in bringing new SCI treatments to
More news about: Christopher & Dana Reeve Foundation
Jan 06, 2026, 09:00 ET WCG Unveils 2026 Trends and Insights Report: Charting a New Era of Readiness, Innovation, and Human-Centric Clinical Research
improving enrollment, retention, and data quality. Technology can enhance access, but trust and empathy remain vital.Cell, Gene & Advanced Therapies: Advanced therapeutics are rapidly expanding, bringing new workflows, safety considerations, and regulatory requirements.
More news about: WCG
Jan 06, 2026, 08:30 ET 'Scripting Possibilities' in Biotechnology: Global Innovators Converge in San Francisco for GenScript's 5th Annual Biotech Forum During JPM Week
year's Forum will explore how transformative advancements, computational revolutions and emerging technologies redefine what is possible in cell and gene therapies (CGTs) and next-generation biotherapeutics. Attendees will engage in forward-looking discussions on the technologies and collaborations shaping
More news about: GenScript Biotech Corporation